Welcome to our dedicated page for Protect Pharmace news (Ticker: PRTT), a resource for investors and traders seeking the latest updates and insights on Protect Pharmace stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Protect Pharmace's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Protect Pharmace's position in the market.
Summary not available.
Summary not available.
Protect Pharmaceutical Corp. (OTC: PRTT) has appointed Ali Yildiz as President and finalized the acquisition of Antarax Capital Danismanlik Limited, marking a significant move for the company. The completion of OTC filings allows the company to present enhanced financials to shareholders. In 2022, Protect Pharmaceutical reported revenues exceeding $90 million and anticipates modest growth in revenue and profitability for 2023. Yildiz expressed enthusiasm for advancing the company's goals with Antarax. The newly acquired Antarax specializes in logistics, providing air, sea, and land transportation services. Protect Pharmaceutical will also seek an auditor to conduct a full audit, promising to keep shareholders updated on progress.
Protect Pharmaceutical Corp. (PRTT) announces a significant change in control of its Preferred Series A shares and the appointment of Ali Yildiz as the new president. Yildiz, who has a proven track record in scaling companies, aims to enhance growth and stability. He is finalizing the acquisition of Antarax Capital Danismanlik Limited, a Turkish firm focused on logistics, which is anticipated to bring substantial shareholder value. This acquisition reflects the company's strategic moves to strengthen its position. Yildiz has expressed commitment to transparency with shareholders and will provide updates through OTC filings.
Protect Pharmaceutical Corporation (OTC:PRTT) has terminated its Share Exchange Agreement due to insufficient legal instruments for conducting transactions in Belarus, as announced on December 12, 2022. The agreement, signed on June 15, 2022, was not executed, with obligations remaining unfulfilled as of December 6, 2022, with no claims against either party. Financial statements for the second and third quarters of 2022 have been adjusted, reflecting the absence of new assets and liabilities. The company specializes in software development and related consulting services across various sectors.
Protect Pharmaceutical Corporation (OTC:PRTT) has acquired CJSC “Inaiapp”, a Belarusian company specializing in corporate software for business digitalization. Inaiapp brings 8 years of blockchain development experience and a solid client base to PRTT. The acquisition aims to enhance PRTT's capabilities in robotic process automation, AI, and machine learning, enabling the creation of more profitable solutions. Nick Greb, President of PRTT, emphasizes the strategic merger of US market presence with advanced technical expertise, aimed at accelerating business processes through innovation and security.
Protect Pharmaceutical Corporation (OTC: PRTT) has announced a share exchange agreement to acquire 100% of CJSC Inaiapp, a leading blockchain solutions provider in the EU. This strategic acquisition aims to enhance PRTT's position in the web 3.0 market and consolidate financial flows for its product development, including multiboxnft.com. Inaiapp brings eight years of blockchain experience and a strong management team, expected to significantly add value to PRTT's operations. The deal underscores PRTT's commitment to emerging tech innovation.
Protect Pharmaceutical Corporation, Inc. (OTC: PRTT) announced a merger with Aetsoft, a blockchain solutions provider, to acquire 100% of Aetsoft’s outstanding shares. This merger aims to enhance PRTT's position in the web 3.0 market and consolidate financial resources for upcoming product launches, including Multibox NFT. Aetsoft, established in 2014, brings significant blockchain development experience and advanced technology solutions, which are expected to add substantial value to PRTT and its shareholders.
Protect Pharmaceutical Corporation (OTC:PRTT) has announced the launch of its all-in-one e-commerce platform for NFTs, MultiBOXnft.com, aiming to capitalize on the growing NFT market projected to reach USD 147.24 billion by 2026. The platform will offer prebuilt design templates, an internal app store, and client support. The beta version is planned for release by the end of 2022, following a business analysis in early May.
Protect Pharmaceutical Corp. (OTC: PRTT) has announced its new project, MultiNFT, aimed at creating a multi-chain NFT marketplace. This platform will support multiple blockchains, including Ethereum, Tron, Binance Smart Chain, Solana, and Polygon, allowing users to seamlessly switch between wallets and optimize trading fees. MultiNFT will enable businesses to easily establish their own NFT marketplaces without significant investments in IT infrastructure. The company anticipates that the NFT market could reach an $80 billion valuation, and PRTT is committed to being a key player in this expanding sector.